Research funding slump alarms head of US cancer institutes

September 25, 2012

The head of the US National Cancer Institute warned Tuesday that the United States could lose its global leadership in research into the disease because of lower spending.

"If you count inflation, our buying power is down by 20%. We are back at the level, in terms of buying power, at the level of 2001," NCI director Harold Varmus told a press conference, referring to expenditure at his institute.

The NCI, part of the National Institutes of Health/NIH, has an annual budget of $5.5 billion.

That is about a sixth of the overall NIH budget of $31 billion and not rising, amid tight budgetary constraints. The NIH is the largest public research institution in the world.

"With the rapid growth of the size of the biomedical community and with the increased expense of how science works, the consequences of advances of technologies, the success rate for grant applicants has fallen to an all-time low, to about 14% of NCI and 17% of NIH from mid 30% during the many years of fiscal growth," stressed Varmus, co-recipient of a for studies of the genetic basis of cancer.

"That is an ironic comment at a time when scientific opportunities in all fields, not only cancer, are remarkably high in part because many prior investments allowed us to understand the as a result of the ," he said.

That means the United States' preeminence in the field could be lost to European or Asian nations, he said.

So "because of these between the promise of science and the ability to fund it, the biomedical ecosystem is under an unusual stress. There is more investment elsewhere in other countries, with more stable investment for research and we are running the risk of losing leadership to Europe and part of Asia," the NCI chief warned.

Explore further: NIH scientists outline steps toward Epstein-Barr virus vaccine

Related Stories

NIH scientists outline steps toward Epstein-Barr virus vaccine

November 2, 2011

Epstein-Barr virus (EBV) infects nine out of ten people worldwide at some point during their lifetimes. Infections in early childhood often cause no disease symptoms, but people infected during adolescence or young adulthood ...

Recommended for you

Combination therapy can prevent cytostatic resistance

November 26, 2015

Researchers at Karolinska Institutet have found a new way of preventing resistance to cytostatics used in the treatment of cancers such as medulloblastoma, the most common form of malignant brain tumour in children. The promising ...

Forecasting the path of breast cancer in a patient

November 23, 2015

USC researchers have developed a mathematical model to forecast metastatic breast cancer survival rates using techniques usually reserved for weather prediction, financial forecasting and surfing the Web.


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.